{"groups":[{"description":"Participants receive a protocol-approved chemotherapy regimen based on the participant and/or physician preference. Participants then receive a protocol-approved adjuvant endocrine therapy for 5-10 years in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Chemo and Endocrine Therapy"},{"description":"Participants receive a protocol-approved endocrine therapy for 5-10 years in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Endocrine Therapy Alone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"28"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"175"},{"groupId":"FG001","numSubjects":"93"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"111"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"41"}],"type":"Other reason"},{"reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"19"}],"type":"Delinquent data"},{"reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"29"}],"type":"Reason under review"},{"reasons":[{"groupId":"FG000","numSubjects":"626"},{"groupId":"FG001","numSubjects":"632"}],"type":"On treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2511"},{"groupId":"FG001","numSubjects":"2507"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1504"},{"groupId":"FG001","numSubjects":"1547"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1007"},{"groupId":"FG001","numSubjects":"960"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"9383 participants were screened and 5083 were randomized to the trial: 2547 to the Chemo and Endocrine Therapy arm and 2536 to the Endocrine Therapy Alone arm. In the Chemo and Endocrine Therapy Arm, 36 were ineligible. In the Endocrine Therapy Alone arm, 29 were ineligible. Ultimately, 5018 participants were eligible in the participant flow: 2511 in the Chemo and Endocrine Therapy arm and 2507 in the Endocrine Therapy Alone arm."}